Table 2.
Summary risk estimates of circulating nesfatin-1 levels and type 2 diabetes mellitus.
| Studies | Random effects SMD (95% CI) | I 2 (%) | P for heterogeneity | |
|---|---|---|---|---|
| Overall | 7 | −0.16 (−0.57, 0.24) | 98 | <0.00001 |
| Subgroup analysis | ||||
| Age | ||||
| <55 | 3 | 0.00 (−0.41, 0.42) | 94 | <0.00001 |
| ≥55 | 4 | −0.08 (−0.53, 0.37) | 96 | <0.00001 |
| BMI | ||||
| <25 | 2 | −0.25 (−0.36, 0.13) | 0 | <0.0001 |
| ≥25 | 5 | −0.04 (−0.36, 0.44) | 96 | <0.00001 |
| HOMA-IR ratio | ||||
| <4 | 3 | 0.29 (−0.37, 0.95) | 98 | <0.00001 |
| ≥4 | 2 | −0.23 (−0.34, −0.12) | 0 | 0.91 |
| Unknown | 2 | −0.32 (−0.53, −0.11) | 33 | 0 |
| Blood sample | ||||
| Plasma | 4 | −0.03 (−0.11, 0.05) | 0 | 0.98 |
| Serum | 3 | −0.24 (−0.33, −0.15) | 97 | <0.00001 |
| T2D criteria | ||||
| WHO | 4 | 0.16 (−0.31, 0.63) | 97 | <0.00001 |
| ADA | 3 | −0.26 (−0.36, −0.16) | 0 | 0.39 |
| Study type | ||||
| Case-control | 4 | −0.08 (−0.53, 0.37) | 96 | <0.00001 |
| Cross-sectional | 3 | 0.00 (−0.41, 0.41) | 94 | <0.00001 |
| Study quality | ||||
| Good | 6 | −0.01 (−0.35, 0.33) | 96 | <0.00001 |
| Moderate | 1 | — | — | — |